Anatara Lifesciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anatara Lifesciences şirketinin toplam hissedar öz sermayesi A$1.4M ve toplam borcu A$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$1.7M ve A$306.8K dir.

Anahtar bilgiler

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranı	n/a
Nakit	AU$982.11k
Eşitlik	AU$1.36m
Toplam yükümlülükler	AU$306.85k
Toplam varlıklar	AU$1.67m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ANR 'nin kısa vadeli varlıkları ( A$1.7M ) kısa vadeli yükümlülüklerini ( A$304.2K ) aşıyor.

Uzun Vadeli Yükümlülükler: ANR şirketinin kısa vadeli varlıkları ( A$1.7M ) uzun vadeli yükümlülüklerini ( A$2.7K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ANR borçsuzdur.

Borcun Azaltılması: ANR son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ANR son raporlanan serbest nakit akışına göre 9 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: ANR serbest nakit akışı tahminlerine göre 8 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Anatara Lifesciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Anatara Lifesciences Limited Auditor Raises 'Going Concern' Doubt

Recent updates

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.75 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 0.5 million.

Anatara Lifesciences Ltd, Annual General Meeting, Nov 14, 2024

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million.

No independent directors

New major risk - Shareholder dilution

Anatara Lifesciences Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.315185 million.

New major risk - Shareholder dilution

No independent directors

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

Anatara Lifesciences Ltd has filed a Follow-on Equity Offering in the amount of AUD 1.055331 million.

No independent directors

Less than half of directors are independent

Anatara Lifesciences Ltd, Annual General Meeting, Nov 10, 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Anatara Lifesciences Ltd Announces board Changes

Insufficient new directors

Insufficient new directors

Anatara Lifesciences Limited, Annual General Meeting, Nov 11, 2022

Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial

Insufficient new directors

Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer

Insufficient new directors

Anatara Lifesciences Updates on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

Anatara Lifesciences Provides Clinical Trials Update

Insufficient new directors

Insufficient new directors

Anatara Lifesciences Limited Provides Clinical Trials Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype

Insufficient new directors

High number of new directors

Anatara Lifesciences Limited Provides Update on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome

Anatara Lifesciences Provides This Update on Clinical Trial Activities

Insider recently sold AU$177k worth of stock

First half 2021 earnings released: AU$0.016 loss per share (vs AU$0.036 loss in 1H 2020)

Anatara Lifesciences Receives Ethics Approval to Start IBS Trial

Anatara Lifesciences Announces Successful Poultry Trial

New 90-day high: AU$0.22

Anatara Lifesciences Limited Announces Cessation of Tracie Elizabeth Ramsdale as Director

Anatara Lifesciences Limited Announces Retirement of Tracie Ramsdale as Non-Executive Director

Anatara Lifesciences Limited Auditor Raises 'Going Concern' Doubt

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin